Stemline Therapeutics (STML) Earning Somewhat Positive Press Coverage, Accern Reports
Media stories about Stemline Therapeutics (NASDAQ:STML) have trended somewhat positive on Monday, Accern Sentiment reports. The research firm identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Stemline Therapeutics earned a news impact score of 0.09 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 46.7372015036422 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news articles that may have impacted Accern Sentiment’s analysis:
- Stemline Therapeutics, Inc. (STML) is at $11.00 per share and Spark Therapeutics, Inc. (ONCE) is listed at $87.10 – Stocks Gallery (stocksgallery.com)
- Biotech’s Leading the way in Life Altering Cancer Therapies – PR Newswire (press release) (prnewswire.com)
- Stemline Therapeutics to Present at Upcoming Investor Conferences – GlobeNewswire (press release) (globenewswire.com)
Shares of Stemline Therapeutics (NASDAQ:STML) opened at 11.00 on Monday. Stemline Therapeutics has a 52 week low of $5.50 and a 52 week high of $14.60. The company’s 50-day moving average is $8.83 and its 200 day moving average is $8.74. The stock’s market cap is $258.01 million.
Stemline Therapeutics (NASDAQ:STML) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.18). The business had revenue of $0.30 million for the quarter, compared to analyst estimates of $0.30 million. Stemline Therapeutics had a negative return on equity of 67.35% and a negative net margin of 4,176.84%. Analysts forecast that Stemline Therapeutics will post ($2.56) earnings per share for the current fiscal year.
Several research analysts recently weighed in on STML shares. Zacks Investment Research downgraded shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, July 18th. Cowen and Company restated a “buy” rating on shares of Stemline Therapeutics in a research report on Wednesday, June 14th. HC Wainwright set a $34.00 price target on shares of Stemline Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 9th. ValuEngine downgraded shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th. Finally, BidaskClub upgraded shares of Stemline Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, July 19th. Two analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. Stemline Therapeutics has a consensus rating of “Buy” and a consensus price target of $29.17.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Stock Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related stocks with our FREE daily email newsletter.